Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616655 · ClinicalTrials.gov registry record · Phase 2
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 456
- Enrollment target
NCT00616655 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 456 participants.
The verdict
NCT00616655, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 456 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
Interventions
- DRUG Placebo
- DRUG eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616655
The ClinicalTrials.gov registry entry for NCT00616655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00616655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616655 about?
NCT00616655 is a clinical study titled "Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects". To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
What is the current status of trial NCT00616655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 456 participants. The study started on 2008-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00616655?
The interventions under investigation include: Placebo (DRUG), eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00616655?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.